Acting as a targeting vector, low concentrations of TAM can be used to guide the delivery of other therapeutic drugs to ER+ BC cells, utilising the anticancer properties and targetability of TAM, whilst decreasing its dose-dependent-toxicity. The gene discussed is ESR1; the disease is breast cancer.